BRPI0714761B8 - formulações compreendendo compostos cíclicos - Google Patents

formulações compreendendo compostos cíclicos

Info

Publication number
BRPI0714761B8
BRPI0714761B8 BRPI0714761A BRPI0714761A BRPI0714761B8 BR PI0714761 B8 BRPI0714761 B8 BR PI0714761B8 BR PI0714761 A BRPI0714761 A BR PI0714761A BR PI0714761 A BRPI0714761 A BR PI0714761A BR PI0714761 B8 BRPI0714761 B8 BR PI0714761B8
Authority
BR
Brazil
Prior art keywords
independently
protonated
active agent
cyclic
dil
Prior art date
Application number
BRPI0714761A
Other languages
English (en)
Portuguese (pt)
Inventor
Botti Paolo
Original Assignee
Capsugel Belgium
Botti Paolo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capsugel Belgium, Botti Paolo filed Critical Capsugel Belgium
Publication of BRPI0714761A2 publication Critical patent/BRPI0714761A2/pt
Publication of BRPI0714761B1 publication Critical patent/BRPI0714761B1/pt
Publication of BRPI0714761B8 publication Critical patent/BRPI0714761B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D323/00Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0714761A 2006-09-27 2007-09-27 formulações compreendendo compostos cíclicos BRPI0714761B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06020286.8 2006-09-27
EP06020286A EP1905454A1 (en) 2006-09-27 2006-09-27 Formulations comprising cyclic compounds
PCT/EP2007/008442 WO2008037484A2 (en) 2006-09-27 2007-09-27 Formulations comprising cyclic compounds

Publications (3)

Publication Number Publication Date
BRPI0714761A2 BRPI0714761A2 (pt) 2013-07-02
BRPI0714761B1 BRPI0714761B1 (pt) 2021-03-23
BRPI0714761B8 true BRPI0714761B8 (pt) 2021-05-25

Family

ID=37728182

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714761A BRPI0714761B8 (pt) 2006-09-27 2007-09-27 formulações compreendendo compostos cíclicos

Country Status (10)

Country Link
US (1) US8513188B2 (cg-RX-API-DMAC7.html)
EP (2) EP1905454A1 (cg-RX-API-DMAC7.html)
JP (1) JP5335677B2 (cg-RX-API-DMAC7.html)
CN (2) CN101557829A (cg-RX-API-DMAC7.html)
AU (1) AU2007302270B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714761B8 (cg-RX-API-DMAC7.html)
CA (1) CA2664568C (cg-RX-API-DMAC7.html)
ES (1) ES2691736T3 (cg-RX-API-DMAC7.html)
IL (1) IL197760A (cg-RX-API-DMAC7.html)
WO (1) WO2008037484A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332929A1 (en) * 2009-11-25 2011-06-15 ArisGen SA Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
CA2782056C (en) 2009-11-25 2021-03-09 Arisgen Sa Mucosal delivery of peptides
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
CN102863358B (zh) * 2012-09-20 2014-02-12 华中农业大学 具有除草活性的化合物及其制备方法
EP3000811B1 (en) * 2014-09-24 2017-11-08 Friedrich-Alexander-Universität Erlangen-Nürnberg Crown Ether Complexes and Methods for Poducing the Same
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN108658264B (zh) * 2018-04-17 2021-05-25 唐山师范学院 多支化聚环氧琥珀酸衍生物阻垢缓蚀剂的制备及其应用方法
CN113527672B (zh) * 2020-03-30 2022-09-20 复旦大学 一种胍基衍生物及其基因递释系统
CN116178887B (zh) * 2023-02-16 2024-10-29 东华大学 一种可降解快递袋材料及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2923787A1 (de) 1979-06-12 1980-12-18 Max Planck Gesellschaft Verfahren zur selektiven bildung von disulfidbruecken in polypeptiden und die dabei erhaltenen produkte als wirkstoffe enthaltende arzneimittel
US4474753A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
CH666813A5 (de) * 1985-12-04 1988-08-31 Dean Hsieh Arzneimittel zur transdermalen verabreichung.
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JP4713798B2 (ja) * 1999-06-29 2011-06-29 マンカインド コーポレイション ペプチドおよびタンパク質の薬学的因子の精製および安定化
US6825314B1 (en) 1999-09-20 2004-11-30 Amato Pharmaceutical Products, Ltd. Process for the preparation of cyclic lactic acid oligomers
JP2005538035A (ja) * 2001-12-11 2005-12-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ グアニジニウム輸送試薬および結合体
JP2006232909A (ja) * 2005-02-23 2006-09-07 Tokai Univ 環状オリゴ乳酸

Also Published As

Publication number Publication date
IL197760A (en) 2016-10-31
CN101541346B (zh) 2014-07-02
JP5335677B2 (ja) 2013-11-06
EP2068934A2 (en) 2009-06-17
IL197760A0 (en) 2009-12-24
EP2068934B1 (en) 2018-07-18
CN101541346A (zh) 2009-09-23
WO2008037484A2 (en) 2008-04-03
CN101557829A (zh) 2009-10-14
AU2007302270A1 (en) 2008-04-03
BRPI0714761A2 (pt) 2013-07-02
EP1905454A1 (en) 2008-04-02
CA2664568C (en) 2015-11-24
EP2068934B8 (en) 2018-09-05
BRPI0714761B1 (pt) 2021-03-23
WO2008037484A3 (en) 2008-12-18
US20100137188A1 (en) 2010-06-03
CA2664568A1 (en) 2008-04-03
US8513188B2 (en) 2013-08-20
ES2691736T3 (es) 2018-11-28
JP2010504934A (ja) 2010-02-18
AU2007302270B2 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
BRPI0714761B8 (pt) formulações compreendendo compostos cíclicos
RU2009137607A (ru) Композиции и наборы для лечения гриппа
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
BR0111126A (pt) Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos
BR0208652A (pt) Composição parenteral reconstituìvel contendo um inibidor de cox-2
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BRPI0819319B8 (pt) análogos de aminoglicosídeo antibacteriano
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
NO20025999D0 (no) Klart, vandig anestetisk preparat
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
BR9808521A (pt) Moléculas que apresentam um grande número de partes ativas.
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
NO20071321L (no) Anti-inflammatoriske midler
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
BRPI0518096A (pt) composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
MX393201B (es) Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades
BRPI0506496B8 (pt) composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese
BRPI0713439A2 (pt) derivados aminados de b-homoandrostanos e b-heteroandrostanos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: CAPSUGEL BELGIUM (BE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2794 DE 23-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.